Gillespie Catherine W, Morin Pamela E
AARP Public Policy Institute, Washington, DC, USA.
OptumLabs, Cambridge, MA, USA.
J Bone Miner Res. 2017 May;32(5):1052-1061. doi: 10.1002/jbmr.3079. Epub 2017 Feb 23.
Timely identification and treatment of osteoporosis following hip fracture is recommended to mitigate future fracture risk, yet prior work has demonstrated a disconnect between evidence-based recommendations and real-world implementation. We sought to describe contemporary patterns of osteoporosis screening and initiation of pharmacotherapy following hip fracture based on medical and pharmacy claims in the OptumLabs™ Data Warehouse. From a national sample, we identified 8349 women aged 50+ years enrolled in private commercial or Medicare Advantage plans with no prior history of osteoporosis diagnosis, osteoporosis pharmacotherapy, or hip fracture who experienced a hip fracture between 2008 and 2013. Just 17.1% and 23.1% of these women had evidence of osteoporosis assessment and/or treatment within 6 or 12 months of their fractures, respectively. Women aged 80+ years were one-third less likely to utilize recommended services within 6 months, compared to those aged 50 to 79 years (13.8% versus 20.8%; p < 0.001). Utilization of bone mass measurement increased significantly among women aged 65+ years over the study period (p < 0.001) while declining among those aged 50 to 64 years (p = 0.2). In contrast, rates of osteoporosis pharmacotherapy remained steady among women aged 50 to 64 years (p = 0.8) yet declined among women aged 65 to 79 years and aged 80+ years (p = 0.07 and p = 0.004, respectively). Accounting for differences in all measured characteristics, receipt of primary care was the strongest and most consistent predictor of osteoporosis assessment or treatment following fracture. © 2017 American Society for Bone and Mineral Research.
建议在髋部骨折后及时识别和治疗骨质疏松症,以降低未来骨折风险,但先前的研究表明,循证建议与实际应用之间存在脱节。我们试图根据OptumLabs™数据仓库中的医疗和药房理赔数据,描述髋部骨折后骨质疏松症筛查和药物治疗起始的当代模式。从全国样本中,我们识别出8349名年龄在50岁及以上、参加私人商业保险或医疗保险优势计划、既往无骨质疏松症诊断、骨质疏松症药物治疗或髋部骨折病史、在2008年至2013年期间发生髋部骨折的女性。这些女性中,分别只有17.1%和23.1%在骨折后6个月或12个月内有骨质疏松症评估和/或治疗的证据。与50至79岁的女性相比,80岁及以上的女性在6个月内使用推荐服务的可能性低三分之一(13.8%对20.8%;p<0.001)。在研究期间,65岁及以上女性的骨量测量使用率显著增加(p<0.001),而50至64岁女性的骨量测量使用率则下降(p=0.2)。相比之下,50至64岁女性的骨质疏松症药物治疗率保持稳定(p=0.8),而65至79岁和80岁及以上女性的骨质疏松症药物治疗率则下降(分别为p=0.07和p=0.004)。考虑到所有测量特征的差异,接受初级保健是骨折后骨质疏松症评估或治疗的最强且最一致的预测因素。©2017美国骨与矿物质研究学会。